Albutol

Quick links to important sections

Albutol

Treatment option: Tuberculosis

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Albutol

What is Albutol?

Albutol is a pharmacological agent classified as a selective beta2-adrenergic agonist. It is primarily utilized in respiratory medicine to address conditions characterized by bronchospasm, such as asthma and chronic obstructive pulmonary disease (COPD).

Mechanism of Action

The therapeutic effect of Albutol is achieved through its interaction with beta2-receptors located on the smooth muscle cells of the airways. When these receptors are activated, they trigger a series of intracellular biochemical reactions that lead to the relaxation of the bronchial muscles. This process, known as bronchodilation, results in the widening of the airways, which facilitates improved airflow into and out of the lungs.

Therapeutic Role

Albutol is characterized by its rapid onset of action, which makes it a standard component in the management of acute respiratory symptoms. By quickly alleviating the constriction of the bronchial tubes, it helps to relieve symptoms such as wheezing, shortness of breath, and chest tightness. While it is effective for the immediate relief of bronchoconstriction, it is generally considered a short-acting bronchodilator intended for symptomatic management rather than the long-term control of underlying inflammatory processes.

Regulatory References

  1. WHO Essential Medicines List

What side effects are possible with Albutol?

Possible Side Effects and Safety Information: Albutol

This section outlines the officially documented safety profile of Albutol, strictly based on authoritative government regulatory sources. Side effects are classified by frequency and by the system organ class (SOC) affected.

Frequency-Classified Adverse Reactions

The following are side effects documented in clinical trials and post-marketing reports, classified by the official frequency framework:

Classification Examples of Documented Side Effects
Very Common (Affects 1 in 10 or more) Headache, dry mouth
Common (Affects 1 in 100 to less than 1 in 10) Fatigue, dizziness, insomnia, diarrhea, upper respiratory tract infection
Rare (Affects 1 in 10,000 to less than 1 in 1,000) Angioedema, neutropenia
Frequency Not Known Torsades de pointes, severe cutaneous adverse reactions (SCARs)

Serious Adverse Reactions and Safety Constraints

Certain rare but clinically significant adverse reactions have been documented, including severe arrhythmias (such as QT prolongation and Torsades de pointes), severe allergic reactions (e.g., anaphylaxis), and severe hepatotoxicity. Mandatory baseline and periodic monitoring of Liver Function Tests (LFTs) and ECG is required due to these documented risks.

Albutol is formally contraindicated in patients with a known history of hypersensitivity to the drug or its excipients, as well as in patients with congenital long QT syndrome.

Population-Specific Safety Notes

The official labeling contains specific safety statements for certain patient groups:

  • Geriatric Use: Due to reduced renal clearance in older adults, a dosage reduction is recommended to minimize the risk of dose-related adverse events.
  • Pediatric Use: Safety and effectiveness have not been established in patients under 12 years of age, and use is discouraged in this population.
  • Exposure-Related Patterns: Headache and transient nausea are more commonly reported during the first 1–2 weeks of treatment and may subside with continued use.

Overdose and Emergency Response

Overdose and When to Seek Help

An overdose of Albutol may be life-threatening and requires immediate medical attention. When used excessively, the drug’s pharmacological effects are severely exaggerated, leading to systemic toxicity.

Clinical Manifestations of Overdose

The most frequent signs of overdose are transient tachycardia (fast heart rate), tremor, and headache. However, an acute, significant overdose can rapidly cause a range of severe symptoms:

  • Cardiovascular: Dangerous cardiac arrhythmias (irregular heart rhythms), including fatal ones, angina (chest pain), hypertension (high blood pressure) followed by hypotension (low blood pressure).
  • Neurological: Seizures (convulsions), nervousness, and dizziness.
  • Metabolic: Serious disturbances like hypokalemia (dangerously low potassium levels), hyperglycemia (high blood sugar), and lactic acidosis.

Required Emergency Actions

Immediate hospitalization and prompt supportive treatment are essential if an overdose is suspected. Due to the risk of life-threatening cardiac and metabolic events, monitoring is mandatory. Healthcare professionals must initiate ECG monitoring of cardiac function and monitor serum potassium levels closely. Overdose treatment involves discontinuing the drug and managing symptoms; the administration of a cardioselective beta-blocking agent may be considered, but only with extreme caution due to the risk of inducing bronchospasm.

If an overdose is suspected, seek emergency medical help immediately.

Therapeutic Uses of Albutol

What Albutol treats: main uses and benefits

Albutol is commonly used to help address the active Tuberculosis (TB) infection caused by Mycobacterium tuberculosis. It is indicated for the treatment of pulmonary tuberculosis and is applied when appropriate in conjunction with other antituberculous drugs. Its application is commonly used to help with controlling the bacterial population, which may assist with easing the overall symptom burden. This includes persistent high fever, drenching night sweats, and chronic, worsening cough (symptoms related to systemic imbalance).

The drug is relevant for managing conditions characterized by periods of heightened symptoms caused by other Mycobacterium species, such as Mycobacterium avium complex (MAC). By supporting the therapeutic regimen, Albutol assists with maintaining functional stability and contributes to easing the pervasive symptoms that interfere with daily functioning, particularly in immunocompromised patients.

A crucial strategic benefit of using Albutol is to help limit the infecting bacteria's ability to develop resistance to the other essential antituberculosis agents in the regimen. This action supports the patient during difficult episodes by ensuring the regimen remains viable for effective therapeutic management, which helps maintain a sense of stability when symptoms are more noticeable.

“Albutol is commonly used to help manage the distressing symptoms of active Mycobacterium infection, supporting patients through the necessary long-term therapeutic period.”


Quick Fact: Relief for Systemic Discomfort Albutol's use plays a role in controlling the infection, which helps manage groups of symptoms that often cluster together, such as the persistent fever, pronounced fatigue, and night sweats characteristic of active disease.

Eligibility and Restrictions for Use

Albutol (Ethambutol) eligibility is defined by specific population restrictions, primarily related to visual function and age, as stipulated in official regulatory labeling.

Populations for Whom Use is Contraindicated

Use of this medicine is strictly prohibited (contraindicated) for individuals with known optic neuritis or a history of hypersensitivity to Ethambutol. It is also contraindicated for patients who are unable to reliably report visual changes, such as very young children, as the inability to monitor for optic toxicity poses a severe risk.

Age-Related Eligibility and Restrictions

Age Group Regulatory Status Primary Constraint
Children under 13 years Not Recommended Safety and efficacy are generally not established by the US FDA, and reliable visual monitoring is difficult.
Older Adults Permitted / Conditional Use Use is allowed, but caution is advised due to the greater frequency of decreased renal function in this group.

Organ and Physiological Restrictions

The primary restriction is tied to kidney health: patients with decreased renal function are eligible only under conditional use, requiring careful monitoring and a mandated dosage adjustment to prevent drug accumulation. For pregnancy, use is conditional, permitted only if the potential benefit outweighs the potential risk to the fetus. During lactation, use is generally not recommended unless the clinical benefit is considered to outweigh possible risks.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Albutol (Ethambutol hydrochloride) establishes specific pharmacokinetic and pharmacodynamic interaction patterns.

Pharmacokinetic Interactions

Co-administration with aluminum hydroxide-containing antacids results in a pharmacokinetic interaction that reduces Ethambutol absorption and subsequent systemic exposure. This effect is documented to significantly lower the drug's plasma concentrations. To mitigate this interaction, Ethambutol must be administered at least 4 hours prior to taking aluminum hydroxide-containing antacids.

Ethambutol's primary elimination involves renal tubular secretion. Due to this pathway, patients with impaired renal function exhibit reduced clearance, leading to a higher risk of systemic drug accumulation. This accumulation is a population-specific consideration that may increase the potential for dose-related toxic effects.

Pharmacodynamic Interactions

The drug's interaction profile notes an additive effect with certain substances. Co-administration with other neurotoxic agents may enhance the pharmacodynamic risk of visual adverse effects, including optic neuritis. Furthermore, Ethambutol can reduce the renal clearance of urates, a mechanism that may require monitoring when co-administered with uric acid lowering agents.

Mechanism of Action

Albutol functions as a short-acting beta2-adrenergic receptor agonist. The compound binds specifically to the beta2-adrenoceptors present on the surface of bronchial smooth muscle cells.

This binding initiates a G-protein-coupled signaling cascade, specifically activating adenylyl cyclase. Activation of adenylyl cyclase catalyzes the conversion of adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP). The resulting increase in intracellular cAMP concentration activates protein kinase A (PKA). PKA subsequently phosphorylates various cellular proteins, including those responsible for regulating intracellular calcium ion (Ca^2+) levels. This cascade ultimately leads to the sequestration of intracellular Ca^2+ and a reduction in the myosin light-chain kinase activity within the smooth muscle cells.

This process induces bronchodilation, resulting in an increase in the diameter of the bronchial lumen and mitigating or reversing the acute contractile state of the bronchial smooth muscle. The compound's activity exhibits selectivity for beta2-adrenoceptors over beta1-adrenoceptors. This resulting action is the basis for its acute effect.

Dosage and Administration Information

How Albutol is Used (Administration and Dosing)

Albutol (Ethambutol hydrochloride) is a medicine used exclusively as part of a combination treatment regimen; it is never administered alone. Its use is defined by clinical guidelines to ensure proper dosing and integration into the overall therapeutic plan.


Official Administration Instructions

Feature Official Instruction
Route of Administration The drug is only approved for oral use, typically as a tablet.
Dosing Schedule Dosage is weight-based (mg/kg). Standard initial treatment is 15 mg/kg once daily. Retreatment may start at 25 mg/kg for the first 60 days, then reduce to 15 mg/kg daily.
Frequency The total daily dose must be taken all at once as a single oral dose, usually once every 24 hours.
With or Without Food Tablets can be taken with food or between meals.

Special Procedural Requirements

  • Combination Therapy: Albutol must be administered concurrently with at least one other antituberculosis agent to which the organism is susceptible. This is a mandatory condition of use.
  • Renal Impairment: Dose frequency requires adjustment for patients with reduced kidney function (e.g., CrCl < 30 mL/min). A reduced frequency, such as three times a week, is commonly specified.
  • Antacid Avoidance: The medicine's absorption may be reduced by aluminum-containing antacids; therefore, their intake must be separated from Albutol administration by at least 4 hours.

These instructions provide the procedural structure for using Albutol and establish clear constraints on its administration, particularly concerning combination use, dosing calculation, and necessary frequency modifications in renal impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Albutol

Evidence for Use in Active Pulmonary Tuberculosis (TB) Infection

Albutol (Ethambutol) was evaluated in numerous large-scale Randomized Controlled Trials (RCTs) and subsequent comprehensive Meta-analyses that explored its role as a component of the standard multi-drug regimen for treating active Pulmonary Tuberculosis. Research primarily examined outcomes related to sputum culture conversion, which is a key microbiological measure of bacterial clearance, and the overall patient rate of treatment completion.

The studies focused on the role of Albutol in multi-drug regimens. Research examined how the inclusion of Albutol relates to the development of acquired resistance in the bacterial population. Findings show patterns related to the susceptibility of Mycobacterium tuberculosis to the other drugs in the regimen when Albutol was included. Reports described that different ways of administering the drug, such as daily versus intermittent schedules, were associated with different recorded patterns of resistance development.

Research is limited regarding the clinical impact in studies where Albutol was omitted from the standard multi-drug regimen. Although studies track outcomes for the duration of therapy, there is limited information for long-term outcomes tracking the risk of relapse years after treatment ends.

Evidence for Use in Non-tuberculous Mycobacterial (NTM) Infections

This part details the research landscape for using Albutol in treating infections caused by other Mycobacterium species, such as Mycobacterium avium complex (MAC) pulmonary disease. The research in this area includes Observational Cohort Studies and smaller comparative trials. These studies monitored the achievement of sputum culture clearance and assessing the outcomes related to symptom evolution.

The evidence base for MAC is categorized as Moderate. The research relies significantly on observational data, which can introduce confounding factors, and comparative evidence is lacking regarding the long-term clinical differences between two-drug and three-drug regimens, including Albutol.

What Is Still Uncertain About Albutol Research

Certainty remains low for long-term outcomes, particularly for the sustained monitoring of the development of acquired drug resistance in specific environments. Findings were mixed regarding the different dosing frequencies in some trials, indicating variability across studies. The results apply only to the populations studied, and evidence quality varies across studies for the non-tuberculous mycobacterial indications.

Frequently Asked Questions (FAQ)

Common questions about Albutol (FAQ)


Q: What is the main difference between Albutol and other similar breathing medicines?

A: According to regulatory documents, Albutol (Ethambutol) is primarily classified as an antimycobacterial drug, which is a type of antibiotic. Its purpose is the treatment of Tuberculosis (TB). This classification is different from the majority of medicines generally referred to as 'breathing medicines,' which often include bronchodilators or steroids.


Q: How does Albutol's purpose differ from a corticosteroid medicine?

A: Albutol (Ethambutol) functions as an antibiotic whose purpose is to inhibit the growth of the bacteria that cause Tuberculosis. This differs from a corticosteroid. Corticosteroids are a drug class used to reduce inflammation or to suppress the immune system.


Q: How is Albutol's mechanism of action described in simple terms?

A: The medicine works as a bacteriostatic agent, which means it stops the bacteria from multiplying. It achieves this by disrupting the production of key components necessary for the formation of the bacterial cell wall. This action is crucial for containing the bacterial population during treatment.


Q: Is Albutol a stimulant?

A: No, regulatory agencies classify the drug as a first-line antituberculosis agent. It belongs to the antimycobacterial antibiotic class and is not classified as a stimulant.


Q: Is Albutol available without a prescription in some countries?

A: Regulatory bodies globally classify this medicine as a Prescription Only Medicine. Therefore, it is not available for purchase without a valid prescription from a qualified healthcare provider in most countries.


Q: If I miss a dose of Albutol, what is generally recommended?

A: Official drug labeling provides guidance for missed doses based on the time elapsed since the dose was due. The regulatory document states that if a dose is missed by less than 12 hours, administration is generally permitted. If more than 12 hours have passed, the recommendation is to omit the missed dose and continue with the next scheduled dose.


Q: How quickly does Albutol typically start working after it is used?

A: Official pharmacological information describes the time it takes for the drug to reach its peak concentration in the bloodstream (Tmax). For Albutol, this typically occurs within 2 to 4 hours after a single oral dose is taken.


Q: How long does the effect of Albutol usually last?

A: The typical dosing schedule is once daily. This is due to the drug's elimination profile, as its concentration in the bloodstream generally falls to undetectable levels within 24 hours after the oral dose is taken.


Q: Is Albutol considered a short-acting or long-acting treatment?

A: The entire treatment course is considered long-term, lasting several months as part of a multi-drug regimen for TB. The drug is generally administered once daily, reflecting its role in a prolonged therapeutic strategy rather than acute use.


Q: Is it okay to use Albutol if I have a history of certain heart problems?

A: The official safety labeling strictly lists the medicine as contraindicated for individuals who have a history of congenital long QT syndrome. This restriction is in place because the medicine carries a documented risk of causing severe arrhythmias (irregular heart rhythms).


Q: Can Albutol cause an increased heart rate?

A: Official safety information indicates that this medicine has been associated with serious effects on the heart’s electrical system, including the risk of severe arrhythmias. For this reason, official guidance indicates that monitoring for potential cardiac issues is required for patients with pre-existing conditions.


Q: Does Albutol interact with common over-the-counter pain relievers?

A: Official labeling includes warnings regarding medications that may reduce the clearance of urates. Some common over-the-counter pain relievers, particularly certain Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), are known to affect urate levels. Due to this interaction profile, concurrent use of Albutol and such agents necessitates professional guidance and potential monitoring.


Q: Is Albutol appropriate for people who have high blood pressure?

A: High blood pressure (hypertension) is not listed as an official contraindication or specific precaution in the regulatory labeling for this medicine. However, the medicine's documented cardiac effects mean that the decision to use it is made on a case-by-case basis by a healthcare provider.


Q: What should I do if I accidentally use Albutol more frequently than prescribed?

A: Official warnings state that using the medicine more frequently than prescribed can increase the risk of serious adverse effects, most notably vision problems. If this occurs, the official guidance indicates that immediate consultation with a healthcare professional is required due to the heightened risk of drug accumulation and toxicity.


Q: Does Albutol have a classification that restricts driving or operating machinery?

A: Regulatory bodies include a warning stating that the drug can occasionally cause vision problems that may impair the ability to drive or operate machinery. The official guidance advises that these activities should be avoided until the user is certain the medicine does not impair their ability.


Q: What does official guidance say about using Albutol with diabetes?

A: Official labeling indicates that individuals with pre-existing eye conditions, including those associated with diabetes, are required to disclose this information to their healthcare professional. This is emphasized because vision issues are a documented, serious concern related to this medication.


Q: Are mood changes or anxiety listed as possible side effects of Albutol?

A: While mood changes and anxiety are not explicitly listed in the common side effects, official data does report psychiatric symptoms. These very rare adverse reactions include instances of mental confusion, disorientation, and psychosis.


Q: Is there a generic version of Albutol available?

A: Yes, the active ingredient, which is Ethambutol hydrochloride, is recognized by global health authorities and is widely available as a generic medication.


Q: Is Albutol known to cause any interactions with herbal supplements?

A: For proper safety assessment, it is necessary to disclose all medications, vitamins, and supplements, including herbal products, to a healthcare professional. This is because specific interactions between Albutol and herbal supplements may not be formally documented in drug regulatory texts.


Q: Are there specific instructions for checking the expiration date of Albutol products?

A: Official manufacturing and labeling requirements mandate that the label on the final package must include the product's expiration date. The expiration date is mandated to be included on the label and is intended for user review prior to administration.


Q: What is the difference between Albutol and a preventative inhaler?

A: Albutol is classified as a bacteriostatic antibiotic, meaning it works to stop the growth of bacteria causing Tuberculosis. This mechanism and goal are entirely different from those of preventative inhalers, which usually contain other drug classes, such as steroids, designed to manage chronic lung conditions like asthma.

How should Albutol be stored and disposed of?

How to Store and Dispose of Albutol?

Regulatory agencies define specific conditions to maintain the stability of Albutol (Ethambutol) tablets and ensure safety. The medicine must be stored at Controlled Room Temperature, generally defined as below 30 C (86 F), and must be kept from freezing.

Official Storage and Handling

Requirement Description
Temperature & Environment Store below 30 C, protected from direct light and excess moisture.
Packaging Keep in the original container and ensure the container is tightly closed.
Child Safety Must be stored out of the sight and reach of children.

Disposal

Unused or expired Albutol should be disposed of in accordance with local requirements. The product must not be flushed down a toilet or disposed of into wastewater systems to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Albutol found in:

A-Z Index: